Products

DreaMed Advisor Pro
DreaMed Diabetes
Clinical Decision Support & Reference
DreaMed Advisor Pro is an FDA-cleared AI-based clinical decision support software that helps healthcare professionals optimize insulin pump settings and provide personalized diabetes management tips for patients with Type 1 and Type 2 diabetes.

See all 1 product →

About DreaMed Diabetes

DreaMed Diabetes is a pioneering healthcare AI company dedicated to transforming diabetes management through advanced decision-support tools. Their flagship product, endo.digital (also known as Advisor Pro), is a cloud-based SaaS platform that provides healthcare professionals with personalized insulin treatment recommendations for individuals with both Type 1 and Type 2 diabetes. The system leverages artificial intelligence to analyze comprehensive data from continuous glucose monitoring (CGM), self-monitoring blood glucose (SMBG), and insulin pumps, offering expert-level insights to optimize insulin pump settings, basal rates, carbohydrate ratios, and correction factors.

This innovative technology addresses the critical global shortage of endocrinology specialists and the increasing challenge of managing the vast amounts of patient data generated by modern diabetes devices. By integrating seamlessly with Electronic Medical Records (EMR) workflows, endo.digital streamlines the diabetes care pathway, reduces clinician burden, and facilitates scalable, expert-level care delivery in both remote and in-person settings. DreaMed has achieved multiple FDA clearances, notably becoming the first and only company to receive FDA clearance for a decision support system that utilizes data from CGM/SMBG and insulin pumps for both Type 1 and Type 2 diabetes.

Focus Areas

AI-based clinical decision support personalized insulin therapy optimization remote patient monitoring Type 1 diabetes management Type 2 diabetes management EMR integration cloud-based platform

Business Intelligence

Key InvestorsMedtronic, eHealth Ventures, A-Labs, OurCrowd, StartUp Health, The Leona M. and Harry B. Helmsley Charitable Trust
PartnershipsYale New Haven Health System, Abbott (data integration for FreeStyle Libre CGM), Billings Clinic, Barbara Davis Center for Diabetes, Texas Children's Hospital, University of Florida
AcquisitionsLicensed its MD-Logic Artificial Pancreas algorithm (GlucoSitter) to Medtronic Diabetes
Technologyendo.digital (cloud-based SaaS platform), MD-Logic algorithm (AI, machine learning, fuzzy logic, event-driven), EMR integration
FDA Clearances5 cleared products (estimated)

What Physicians Need to Know

AI-based Clinical Decision Support
DreaMed's endo.digital platform (formerly Advisor Pro) utilizes a proprietary AI-powered algorithm, MD Logic, to analyze comprehensive patient data and generate personalized insulin treatment recommendations. This system is designed to emulate the decision-making process of expert endocrinologists.
Personalized Insulin Therapy Optimization
The platform provides specific recommendations for optimizing insulin pump settings (basal rate, carbohydrate ratio, correction factor) and supports patients on multiple daily injections (MDI). It processes data from continuous glucose monitors (CGM), self-monitoring blood glucose (SMBG) meters, and insulin pumps.
Remote Patient Monitoring
As a cloud-based SaaS platform, endo.digital facilitates efficient remote management of diabetes, allowing healthcare providers to monitor patients and adjust therapy plans virtually.
Type 1 & Type 2 Diabetes Management
DreaMed's endo.digital is the only FDA-cleared decision support software for both Type 1 and Type 2 diabetes, covering patients using insulin pumps or multiple daily injections.
EMR Integration
The platform offers seamless integration with Electronic Medical Records (EMR) systems, allowing clinicians to access the platform directly from patient records and automatically populate glucose statistics and approved care plans into EMR flowsheets and progress notes.
Cloud-based Platform
endo.digital is a cutting-edge, cloud-based SaaS platform that provides an end-to-end diabetes care pathway solution, enabling management across all care settings, whether in-person or remote.
Physician Tip

DreaMed Diabetes' endo.digital platform is designed to significantly enhance clinical workflow and patient outcomes. Physicians can expect to reduce time spent on data analysis (up to 9 minutes per patient visit), gain expert-level insulin titration recommendations, and standardize treatment approaches across their teams. The platform helps overcome data overload from various devices, enabling more focused patient interaction and supporting telemedicine services. Its FDA clearances for both Type 1 and Type 2 diabetes, across pump and MDI therapies, provide a broad scope of application. Furthermore, the automated documentation for billing (e.g., CGM code 95251) can increase reimbursement opportunities and improve financial outcomes for practices.

DreaMed's endo.digital platform is compatible with a vast majority of diabetes devices on the market, including various Continuous Glucose Monitors (CGM) like Dexcom G4, G6, G7, Abbott FreeStyle Libre (Pro and 3), and Self-Monitoring Blood Glucose (SMBG) meters such as OneTouch Ultra 2, OneTouch Verio Flex, Ascencia Contour Next Link, and Trividia True Metrix Pro. It also integrates with insulin pumps like Tandem T:slim, Tandem T:Slim X2, Insulet Omnipod DASH, and Medtronic 630G/723. Data is acquired via cloud-to-cloud transfer or USB cable plug-in to a provided uploader, and the platform integrates with data management systems like Tidepool and Glooko. EMR integration is a key feature, with successful deployments demonstrating seamless workflow integration.

Products by DreaMed Diabetes

1 product in the directory

DreaMed Advisor Pro
DreaMed Diabetes
Clinical Decision Support & Reference
DreaMed Advisor Pro is an FDA-cleared AI-based clinical decision support software that helps healthcare professionals optimize insulin pump settings and provide personalized diabetes management tips for patients with Type 1 and Type 2 diabetes.

What the Web Says

DreaMed Diabetes is an Israeli medical technology company that provides AI-based clinical decision support systems for diabetes management, primarily through its endo.digital platform and Advisor Pro tool. The company's solutions aim to simplify diabetes care by processing patient data from various devices to offer insulin dosing recommendations to healthcare providers. This technology has received FDA clearance for both Type 1 and Type 2 diabetes patients, including those on multiple daily injections or insulin pumps. Reviews suggest a positive impact on workflow efficiency for clinicians and improved patient outcomes.

Overall: Positive

Strengths

  • AI-driven insulin dosing recommendations simplify complex calculations for healthcare providers.
  • Reduces the number of steps in the diabetes management process, saving clinicians time.
  • FDA-cleared for both Type 1 and Type 2 diabetes, expanding itsu9002u7528u8303u56f4.
  • Can improve A1C levels and increase time in range for patients.
  • Integrates with Electronic Medical Records (EMR) for improved workflow efficiency in clinics.
  • Supports remote care and can be a valuable resource for patients without easy access to endocrinologists.

Limitations

  • The DreaMed Diary app has a reported issue where the keyboard covers the text field on iPhones, making typing difficult.
  • The DreaMed Diary app currently lacks individual login accounts for managing multiple patients, which could be inconvenient for some users.
  • Limited public reviews available on platforms like G2, Glassdoor, Capterra, and Reddit, making it difficult to gauge widespread user sentiment.
  • The DreaMed Diary app is prescription-only, limiting direct access for individual patients.
  • Some Reddit discussions about diabetes apps do not mention DreaMed Diabetes, suggesting it may not be as widely known or used by individual patients compared to other apps.

Based on reviews from: StartUp Health, G2, Fierce Biotech, accessdata.fda.gov, Business Wire, App Store, Reddit

Last updated: 2026-07-18

Videos

News, demos, and interviews about DreaMed Diabetes.

Loading videos...

Videos load interactively. If none appear, search YouTube for DreaMed Diabetes →

View all on YouTube

Press & Coverage

Ctech
DreaMed secures $3M and strategic deals amid CEO's reserve IDF duty
DreaMed Diabetes raised $3 million in a funding round led by eHealth Ventures in August 2024, alongside signing strategic data integration agreements with Abbott and partnerships with health systems like Yale New Haven Health. This funding and these collaborations aim to support the commercialization and broader adoption of its AI-based endo.digital platform.
2024-08
NoCamels
AI Diabetes Management Startup Strikes Deals, Expands In US
DreaMed Diabetes announced new deals with US health systems, including Yale New Haven Health, and a data integration agreement with Abbott for its FreeStyle Libre CGM data, expanding its presence in the US market. The company also closed a $3 million financing round led by eHealth Ventures.
2024-08
Archives of Medical Science u2013 Atherosclerotic Diseases
Diabetes management in the era of artificial intelligence
A June 2024 article highlights DreaMed Diabetes' Advisor Pro as an FDA-authorized AI-powered device that suggests remote insulin dose adjustments by analyzing CGM and self-monitoring blood glucose data, enabling doctors to optimize patient care. The article discusses the potential of AI to improve diabetes management, including screening, diagnosis, and personalized therapies.
2024-06
Business Wire
DreaMed Diabetes Deploys Diabetes Data Management and Clinical Decision Support Device Into Patients' Electronic Medical Records at Yale New Haven Health
In January 2023, DreaMed Diabetes partnered with Yale New Haven Health System to deploy its endo.digital clinical decision support system as a fully integrated component of Northeast Medical Group's EMR workflow. This integration allows all providers in the patient's care continuum to access expert-level diabetes care and personalized treatment recommendations.
2023-01
Fierce Biotech
DreaMed Diabetes' 'digital endocrinologist' AI expands to Type 2 diabetes with FDA green light
DreaMed Diabetes received FDA clearance in October 2021 for its Advisor Pro digital platform, expanding its AI-powered clinical decision support system to include patients with Type 2 diabetes. This clearance allows the platform to assist healthcare providers in managing a broader population of diabetes patients using insulin pumps or frequent injections.
2021-10
MD+DI Online
DreaMed Rolls Out AI-Powered Digital Diabetes Management
In October 2021, DreaMed Diabetes deployed its Advisor Pro digital diabetes management platform in a top 10 metropolitan U.S. children's hospital, following its fourth FDA clearance for Type 1 and Type 2 diabetes solutions. The platform provides AI-based clinical decision support for remote insulin management.
2021-10
DreaMed Diabetes (Blog/Press Release)
What's In The Nature Medicine Study Featuring Advisor Pro?
A September 2020 study published in Nature Medicine demonstrated that DreaMed's Advisor Pro insulin dosing adjustments were non-inferior to those provided by expert physicians for Type 1 diabetes patients. The study highlighted the system's effectiveness in improving patient outcomes and physician satisfaction.
2020-09
Business Wire
DreaMed's Automated Insulin Delivery Technology Is Featured in Medtronic's New System Bringing Its Vision of Helping People With Type 1 Diabetes to Life
In June 2020, DreaMed Diabetes announced the use of its Artificial Pancreas algorithm in Medtronic's new CE Marked MiniMed 780G Advanced Hybrid Closed Loop system. This collaboration, dating back to 2015, integrates DreaMed's technology to optimize insulin delivery for Type 1 diabetes patients.
2020-06

Frequently Asked Questions

DreaMed Diabetes' flagship product, endo.digital (formerly DreaMed Advisor Pro), is an AI-based clinical decision support system designed to optimize insulin therapy. It utilizes a proprietary 'MD Logic' algorithm to analyze data from continuous glucose monitors (CGM), self-monitoring blood glucose (SMBG) devices, and insulin pumps, generating personalized recommendations for healthcare providers.
The endo.digital platform provides personalized recommendations for adjusting insulin pump settings, including basal rates, carbohydrate ratios, and correction factors, along with management tips. It holds FDA clearance to assist healthcare providers in managing both Type 1 and Type 2 diabetes patients, whether they use insulin pumps or multiple daily injections.
DreaMed's cloud-based platform facilitates remote patient monitoring by allowing data from various diabetes devices to be uploaded and analyzed. Healthcare providers can then review the AI-generated recommendations and share optimized treatment plans with patients remotely via app or email, supporting efficient telemedicine workflows.
The endo.digital platform offers seamless EMR integration, as demonstrated by its deployment within Yale New Haven Health's EMR workflow. This integration allows for automatic population of patient information into EMR notes and flowsheets, aiming to simplify workflows, reduce manual documentation, and improve operational efficiency for care teams.
DreaMed's endo.digital is a cloud-based SaaS platform that prioritizes data privacy and security. The company adheres to stringent regulatory standards, including HIPAA, GDPR, and ISO 27001, and has received multiple FDA clearances for its clinical decision support system.
DreaMed Diabetes has established key partnerships with data management platforms like Glooko and Tidepool to integrate patient device data. Additionally, they have strategic collaborations with prominent health systems such as Yale New Haven Health and Billings Clinic, and a recent data integration agreement with Abbott for FreeStyle Libre CGM data, expanding their market presence and data sources.
Founded in 2014 as a spin-off from Schneider Children's Medical Center, DreaMed Diabetes initially developed an artificial pancreas technology licensed to Medtronic. The company has secured multiple FDA clearances for its endo.digital platform and recently raised $3 million in funding, indicating ongoing investment and a focus on expanding its AI-driven diabetes management solutions.

Related Companies

e4health is a healthcare consulting and services company that provides innovative solutions to hospitals, health systems, outpatient providers, and physician practices. The company focuses on addressing data, quality, and revenue challenges within the healthcare ecosystem. Their services are designed to streamline health information data and workflows, optimize coding, quality, and clinical documentation integrity processes, and […]

PayZen is a healthcare fintech company that leverages AI and automation to address the growing challenge of healthcare affordability for patients and financial stability for providers. The platform offers personalized, interest-free payment plans, extending up to 60 months, tailored to each patient’s ability to pay. This approach aims to remove financial barriers to care, allowing […]

Healthcare Finance.AI is dedicated to optimizing healthcare revenue cycles through cutting-edge AI technologies. The company aims to improve financial outcomes for healthcare providers while supporting their commitment to quality care and efficiency. Their solutions are designed to enhance revenue cycle efficiency, reduce claim turnaround times, and improve patient billing accuracy. Their platform leverages advanced analytics […]

The American Academy of Family Physicians (AAFP) is one of the largest national medical organizations in the United States, representing over 130,000 family physicians, residents, and medical students. Founded in 1947, its core mission is to improve the health of patients, families, and communities by serving the needs of its members with professionalism and creativity. […]

Imperial College Business School, a faculty of Imperial College London, is a leading institution that integrates business education with science, engineering, medicine, and technology. For physicians and healthcare providers, the Business School offers specialized programs and research focused on the intersection of AI, digital transformation, and healthcare management. Their curriculum is designed to equip healthcare […]

Columbia University, through its online learning initiative ColumbiaX on edX, offers a range of courses, including those focused on healthcare AI. The university is a global leader in research, teaching, and public impact, consistently ranked among top universities. Their online offerings reflect a commitment to academic excellence and expanding access to high-quality education worldwide. For […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.